ストックスクリーナーアプリを入手
66.04
1.71%
1.11
アフターアワーズ：
66.04
Incyte Corp (INCY) 最新ニュース
Vitiligo Market Growth Trends and Forecast Report 2025-2033Rising Awareness, Diagnostic Advances, Innovative Therapies, and Expanding Global Healthcare Access - Yahoo Finance
Incyte’s SWOT analysis: stock faces patent cliff amid pipeline potential - Investing.com
Incyte’s SWOT analysis: stock faces patent cliff amid pipeline potential By Investing.com - Investing.com India
Incyte to Present at Upcoming Investor Conference on Monday, June 9, 2025 at 11:20 am (ET) - BioSpace
Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight - GlobeNewswire Inc.
Incyte (INCY) Target Price Raised by Truist Securities | INCY St - GuruFocus
Incyte (INCY) Sees Price Target Boost from Truist Analyst | INCY Stock News - GuruFocus
Incyte to Present at Upcoming Investor Conference - Business Wire
3 Reasons INCY is Risky and 1 Stock to Buy Instead - Yahoo Finance
FDA approves Incyte’s retifanlimab combo for SCAC treatment - Yahoo Finance
Is Wall Street Bullish or Bearish on Incyte Stock? - inkl
Is Wall Street Bullish Or Bearish On Incyte Stock? - Barchart.com
Incyte Gets FDA Approval for Zynyz in New Cancer Indication - MSN
Incyte adds more FDA approvals for Zynyz in cancer - BioWorld MedTech
FDA Approves Incyte's (INCY) Zynyz for Advanced Anal Cancer Trea - GuruFocus
Incyte granted FDA approval of Zynyz for SCAC - The Pharma Letter
Incyte’s PD-1 Blocker Wins First-Line Anal Cancer Approval - BioSpace
No Article III Appellate Standing Under the Sun - Lexology
FDA Broadens Approval for Incyte's Zynyz in Cancer Treatments (INCY) - GuruFocus
FDA Approves Incyte's (INCY) Zynyz for Advanced Anal Cancer Treatment | INCY Stock News - GuruFocus
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States | INCY Stock News - GuruFocus
FDA approves new anal cancer treatment Zynyz by Incyte - Investing.com
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States – Company AnnouncementFT.com - Financial Times
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States - The Joplin Globe
Pharma Company Incyte Settles Novartis Royalties Dispute for $280 Million, SEC Records Show - Law.com
Incyte Corporation (INCY) Reaches Settlement with Novartis Over Royalty Dispute - GuruFocus
Incyte (INCY) Reaches $280M Settlement with Novartis Over Jakafi Royalties - GuruFocus
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy - openPR.com
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics - Barchart.com
Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Incyte settles royalty dispute with Novartis for $280 million - Investing.com
Incyte at Bank of America Conference: Strategic Insights on Growth - Investing.com
Incyte To Present At 2025 BofA Securities Health Care Conference; Webcast At 4:40 PM ET - Nasdaq
Latest Federal Court Cases: Pharmaceutical Patent Protections - JD Supra
INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance - Yahoo Finance
Incyte Corporation: Here Are The 5 Major Factors Propelling Our ‘Outperform’ Rating! - Smartkarma
Steroid Refactory Acute Graft-Versus-Host Disease Market Set - openPR.com
Incyte Co. (NASDAQ:INCY) Holdings Raised by Stifel Financial Corp - Defense World
Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecast - MSN
New Incyte Suit Targets Broader Apotex Bid to Sell Jakafi Rival - Bloomberg Law News
Sun shines on Leqselvi at Federal Circuit - BioWorld MedTech
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2025 - BioSpace
Fed. Circ. Clears Way For Sun Pharma Alopecia Drug - Law360
US panel, finding no irreparable harm, vacates injunction against Sun Pharma - MLex
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus
Incyte Can’t Keep Sun’s Hair Drug Off Market, Appeals Court Says - Bloomberg Law News
Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com
Novartis, Incyte Settle Drug Royalty Fight On Eve Of Trial - Law360
William Blair Has Optimistic Outlook of Incyte Q4 Earnings - Defense World
Polycythemia vera Market: Epidemiology, Therapies, - openPR.com
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com
Incyte (INCY) Target Price Raised Following Strong Q1 Performanc - GuruFocus
0.95%
大文字化:
|
ボリューム (24 時間):